A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma

Oncology

Volumn 71, Issue 5-6, 2007, Pages 369-373

  Tsuji, Hiroyuki ^a   Kiba, Takayoshi ^a   Nagata, Motoki ^b   Inoue, Toshiya ^b,c   Yukawa, Hisaya ^b   Yamashita, Toshio ^b   Shimode, Yuzo ^a   Murata, Hideyuki ^a   Nagata, Kenji ^d   Tomoda, Koichi ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c Saiseikai Noe Hospital   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Chemoradiation; Head and neck cancer; Phase I study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DYSPHAGIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNX CARCINOMA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE;

ADULT; AGED; DERMATITIS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; GLOTTIS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSITIS; OXONIC ACID; TEGAFUR; TREATMENT OUTCOME;

EID: 35348816402     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108385     Document Type: Article

References (27)

1. Piccirillo JF: Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593-602.
2. Marcial VA, Pajak TF: Radiation therapy alone or in combination with surgery in head and neck cancer. Cancer 1985;55:2259-2265.
3. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB: Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786-1792.
4. Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M: Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004;40:713-719.
5. National Cancer Institute: National Cancer Institute Common Toxicity Criteria (version 2). Bethesda, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 1999.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
7. Cerezo L, Millan I, Torre A, Aragon G, Otero J: Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer 1992;69:1224-1234.
8. Snyder MC, Lydiatt WM, Lydiatt DD: Glottic cancer. 2006. http://www.emedicine.com/ ent/topic688.htm.
9. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M: Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64:77-82.
10. Lo TC, Wiley AL Jr, Ansfield FJ, Brandenburg JH, Davis HL Jr, Gollin FF, Johnson RO, Ramirez G, Vermund H: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976;126:229-235.
11. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8:1923-1933.
12. Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-1350.
13. Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, Friedman MA, Kohler M, McWhirter K, Carter SK: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-1418.
14. Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:803-806.
15. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29-37.
16. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464.
17. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L; Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-589.
18. Adelstein DJ, Kalish LA, Adams GL, Wagner H Jr, Oken MM, Remick SC, Mansour EG, Haselow RE: Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136-2142.
19. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-1128.
20. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, Endrizzi L, Bari M, Sampognaro E, Balli M, Gava A, Pappagallo GL, Fiorention MV: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
21. Athanasiadis I, Taylor S 4th, Vokes EE, Pelzer HJ, Rademaker A, Mittal BB, Ganzenko N, Blough R, Lester EP, Kies MS: Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck: a long-term analysis for the Illinois Cancer Center. Cancer 1997;79:588-594.
22. Adelstein DJ: Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1999;13:689-698.
23. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
24. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998;9:817-823.
25. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
26. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B; S-1 Cooperative Study Group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001;28:1381-1390.
27. Ziras N, Tsoutsou P, Koliarakis N, Magdalinos N, Sarris G, Potamianou A, Paraskevaides M, Synodinou M, Chrysanthou K, Karageorgis P, Athanassiou AE: Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5-fluorouracil and folinic acid in locally advanced rectal cancer. J BUON 2004;9:255-261.